Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease?

Current Opinion in Pulmonary Medicine

Volumn 11, Issue 2, 2005, Pages 121-128

  Tashkin, Donald P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

COPD; Inhaled corticosteroids; Long acting 2 agonist; Theophylline; Tiotropium

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FORMOTEROL; IPRATROPIUM BROMIDE; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ANGIONEUROTIC EDEMA; BLADDER DISEASE; BLADDER NECK STENOSIS; BONE DENSITY; BRONCHODILATATION; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SELECTIVITY; DYSPHONIA; DYSPNEA; FRACTURE; GLAUCOMA; HEALTH CARE COST; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HOSPITAL COST; HUMAN; LUNG FUNCTION; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SINUS TACHYCARDIA; SKIN BRUISING; SUDDEN DEATH; SYSTEMIC DISEASE; TACHYCARDIA; THRUSH; TREATMENT OUTCOME; XEROSTOMIA;

EID: 14044265066     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200503000-00004     Document Type: Review

References (91)

1. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. National Heart Lung and Blood Institute/World Health Organization; 2003. Available at: http://www.goldcopd.com/revised.pdf. Accessed November 14, 2003. This authoritative report summarizes the current state of knowledge in COPD, including a section on the clinical management of COPD and recommendations for therapy based on different levels of evidence. Periodic updates will be available on the Internet.
2. Celli BR, MacNee W, ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946. This document is the most recent update of the position papers on COPD published in 1995 by the American Thoracic Society and the European Respiratory Society. The American Thoracic Society/European Respiratory Society guidelines usefully complement the Global Initiative for Chronic Obstructive Lung Disease report with more specific recommendations concerning oxygen therapy, pulmonary rehabilitation, noninvasive ventilation, surgical therapies, sleep, air travel, and endof-life issues.
3. National Institute for Clinical Excellence: Chronic obstructive pulmonary disease. Thorax 2004; 59:1-232. This is a comprehensive national clinical guideline developed by the National Institute for Clinical Excellence in the United Kingdom. It is the first set of guidelines to collate and examine systematically all the evidence in the published literature concerning the diagnosis and care of COPD.
4. O'Donnell DE, Fluge T, Gerken F, et al. Effect of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832-840. This randomized, double-blind, placebo-controlled clinical trial is the first to demonstrate progressive and significant increases in exercise endurance and reductions in perceived breathlessness during exercise during a 6-week course of treatment with tiotropium compared with placebo. These results were paralleled by sustained reductions in hyperinflation both at rest and during exercise, thereby providing a plausible explanation for the improvements in exercise tolerance and exertional dyspnea as a result of increases in inspiratory capacity that allowed greater expansion of the tidal volume during the hyperpnea of exercise.
5. Belman MJ, Botnick WC, Shin JW: Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with COPD. Am J Respir Crit Care Med 1990; 153:967-975.
6. Tashkin D, Kesten S: Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123:1441-1449.
7. Muir JF, Benhamou D, Cuvelier A, et al. FEV1 reversibility does not adequately predict effect of formoterol Aerolizer in chronic obstructive pulmonary disease. Int J Clin Pract 2004; 58:457-464.
8. Mahler D: The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2002; 110:S298-S303.
9. 1. The Lung Health Study. JAMA 1994; 272:1497-1505.
10. Kelloway JS, Wyatt RA, Adlis SA: Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994; 154:1349-1352.
11. Chapman K: Anticholinergic bronchodilators for adult obstructive airways disease. Am J Med 1991; 91:13S-16S.
12. Ferguson GT, Cherniack RM: Management of chronic obstructive pulmonary disease. N Engl J Med 1993; 328:1017-1022.
13. Statement ATS: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:S78-S121.
14. Siafakas NM, Vermeire P, Pride NB, et al. ERS consensus statement: optimal assessment and management of chronic obstructive pulmonary disease. Eur Respir J 1995; 8:1398-1420.
15. The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the 16.
16. COMBIVENT Inhalation Aerosol Study Group: In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest 1994; 105:1411-1419.
17. Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115:635-641.
18. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115:957-965.
19. 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1087-1092.
20. Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:778-784.
21. Wadbo M, Lofdahy C-G, Larsson K, et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled trial. Eur Respir J 2002; 20:1138-1146.
22. Stahl E, Wadbo M, Bentsson T, et al. Health-related quality of life, symptoms, exercise capacity and lung function during treatment for moderate to severe COPD. J Drug Assess 2002; 5:81-94.
23. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19:209-216.
24. van Noord JA, Bantje TA, Eland ME, et al. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000; 55:289-294.
25. Husereau DR, Shukla VK, Boucher M, et al. Long acting beta-2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomized controlled clinical trials. BMC Pulm Med 2004; 4:7. http://www.Biomedcentral.com/info/authors/.
26. Keam SJ, Keating GM: Tiotropium bromide: a review of its use as maintenance therapy in patients with COPD. Treat Respir Med 2004; 3:247-268.
27. Appleton S, Poole P, Smith B, et al. Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev 2002; 3:CD001104.
28. Sin DD, McAlister FA, Paul Man SF, et al. Contemporary management of chronic obstructive pulmonary disease. JAMA 2003; 290:2301-2312.
29. This is a useful, comprehensive, systematic review of randomized controlled trials of the effect of various interventions in patients with COPD, including long-acting bronchodilators, inhaled corticosteroids, nocturnal noninvasive ventilation, pulmonary rehabilitation, domiciliary oxygen therapy, and disease management programs, on a variety of outcomes. Data from clinical trials from 1980 to May 2002 are included in the review.
30. Tashkin DP, Cooper CB: The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125:249-259.
31. Cazzola M, Matera MG, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995; 89:357-362.
32. Celik G, Kayacan O, Beder S, et al. Formoterol and salmeterol in patients with reversible obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration (Herrlisheim) 1999; 66:434-439.
33. Jones PW, Wilson K, Sondhi S: Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. Respir Med 2003; 97:20-26.
34. Hogan TJ, Geddes R, Gonzalez ER: An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. Clin Ther 2003; 25:285-297.
35. Ferguson GT, Funck-Bretano C, Fischer T, et al. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123:1817-1824.
36. This study conducted a pooled analysis of cardiovascular safety data from seven randomized, double-blind, controlled studies of 12 to 52 weeks that included salmeterol (n = 1410) and placebo (n = 1443) arms. Salmeterol was not found to increase the risk of cardiovascular adverse events.
37. Rabe KF: State of the art in β-agonist therapy: a safety review of long-acting agents. Int J Clin Pract 2003; 57:689-697.
38. Goldkorn A, Diotto P, Burgess C, et al. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol. Respirology 2004; 9:102-108.
39. Cazzola M, Imperatore F, Salzillo A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114:411-415.
40. Au DH, Lemaitre RN, Curtis JR, et al. The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists. Am J Respir Crit Care Med 2000; 161:827-830.
41. Salpeter SR, Ormiston TM, Salpeter ED: Cardiovascular effects of β-agonists in patients with asthma and COPD. Chest 2004; 125:2309-2321.
42. 2-agonists increased heart rate and reduced serum potassium levels significantly, whereas multiple doses significantly increased the risk for a cardiovascular event compared with placebo.
43. Product Monograph: Spiriva Handihaler, Tiotropium Bromide. Ridgefield, CT: Boehringer-Ingelheim Pharmaceuticals; and New York: Pfizer; 2004.
44. Anon.: Tiotropium (Spiriva) for COPD. Med Lett Drugs Ther 2004; 46:41-42.
45. Oostenbrink JB, Rutten-van Moklen MJ, van Noord JA, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004; 23:241-249.
46. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217-224.
47. Friedman M, Menjoge SS, Anton SF, et al. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics 2004; 22:741-749.
48. O'Donnell DE, Lam M, Webb KA: Measurement of symptoms, lung hyperinflation and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:1557-1565.
49. Taube C, Lehnigk B, Paasch K, et al. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162:216-220.
50. Boni E, Corda L, Franchini D, et al. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest. Thorax 2002; 57:528-532.
51. Bouros D, Kottakis J, Le Gros V, et al. Effects of formoterol and salmeterolon resting inspiratory capacity in COPD patients with poor FEV1 reversibility. Curr Med Res Opin 2004; 20:581-586.
52. Pavia D, Thomson ML: Inhibition of mucociliary clearance from the human lung by hyoscine. Lancet 1971; 1:449-450.
53. Annis P, Landa J, Lichtiger M: Effects of atropine on velocity of tracheal mucus in anesthetized patients. Anaesthesiology 1976; 44:74-77.
54. Francis RA, Thomson ML, Pavia D, et al. Ipratropium bromide: mucociliary clearance rate and airway resistance in normal subjects. Br J Dis Chest 1977; 71:173-178.
55. Foster WM, Langenback EG, Glaser ML, et al. Acute effect of ipratropium bromide at therapeutic dose on mucus transport of adult asthmatics. Eur J Respir Dis 1983; 64:544-557.
56. Hasani A, Toms N, Agnew JE, et al. The effect of tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004; 125:1726-1734.
57. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47-55.
58. Donohue JF, Menjoge S, Kesten S: Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003; 97:1014-1020.
59. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58:399-404.
60. This report presents the data from two 6-month randomized, double-blind, placebo-controlled trials comparing tiotropium head-to-head with salmeterol in COPD patients. It is one of the only two published direct comparison studies with salmeterol in COPD and complements the report of Donohue et al. [54]. Tiotropium was significantly more effective than salmeterol in improving lung function and was numerically superior to salmeterol in improving quality of life and breathlessness and delaying the time to the first exacerbation, outcomes for which tiotropium, but not salmeterol, was significantly different from placebo.
61. Barnes PJ: Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003; 167:813-818.
62. This review article provides a fresh perspective on the bronchodilator and anti-inflammatory effects of theophylline, including the purported mechanisms of action of theophylline, such as activation of histone deacetylases that influence the action of corticosteroids. The author also points out the possible unique utility of theophylline in COPD in view of its anti-inflammatory effects and its possible role in reversing steroid resistance induced by oxidative stress.
63. Murciano D, Aubier M, Lecocguic Y, et al. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med 1984; 311:349-353.
64. Ziment I: Theophylline and mucociliary clearance. Chest 1987; 92:38S-43S.
65. Mathay RA, Mahler DA: Theophylline improves global cardiac function and reduces dyspnea in chronic obstructive pulmonary disease. J Allergy Clin Immunol 1986; 78:793-799.
66. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121:1058-1069.
67. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119:1661-1670.
68. Paggiaro PL, Dahl R, Bakran I, et al. Multicentre randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease: International COPD Study Group. Lancet 1998; 351:773-780.
69. Weir DC, Bale GA, Bright P, et al. A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clin Exp Allergy 1999; 29:S125-S128.
70. Bourbeau J, Rouleau MY, Boucher S: Randomized controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998; 53:477-482.
71. van der Valk P, Monninkhof E, van der Palin J, et al. Effect of discontinuing inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166:1358-1363.
72. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340:1948-1953.
73. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999; 353:1819-1823.
74. The Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. Lung Health Study II. N Engl J Med 2000; 343:1902-1909.
75. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-1303.
76. MacNee W, Calverley PMA: Chronic obstructive pulmonary disease 7: management of COPD. Thorax 2003; 58:261-265.
77. Alsaeedi A, Sin DD, McAlister FA: The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113:59-65.
78. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:1084-1091.
79. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361:449-456.
80. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124:834-843.
81. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/ formoterol in the management of chronic obstructive disease. Eur Respir J 2003; 21:74-81.
82. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:912-919.
83. Tashkin DP, Murray R, Murray HE, et al. Skin manifestations of inhaled corticosteroids: results from Lung Health Study II, a randomized controlled clinical trial. Chest 2004; 126:1123-1133.
84. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001; 345:941-947.
85. Scanlon PD, Connett JE, Wise RA, et al., for the Lung Health Study Research Group: Loss of bone density associated with the use of an inhaled corticosteroid in adults with chronic obstructive pulmonary disease: Lung Health Study II. Am J Respir Crit Care Med 2004; 170:1302-1309.
86. Hubbard RB, Smith CJ, Smeeth L, et al. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002; 166:1563-1566.
87. Cumming RG, Mitchell P, Leader SR: Use of inhaled corticosteroids and the risks of cataracts. N Engl J Med 1997; 337:8-14.
88. Garb E, Le Lorier J, Boivin FJ, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma JAMA 1997; 277:722-727.
89. Cazzola M, Marco FD, Santus P, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004; 17:35-39.
90. van Noord JA, Aumann J, Janssens E, et al. Tiotropium maintenance therapy in patients with COPD and the 24-h spirometric benefit of adding once or twice daily formoterol during 2-week treatment periods [abstract]. Am J Respir Crit Care Med 2003; 168:A95.
91. van Noord JA, Aumann J, Janssens E, et al. Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD [abstract]. Am J Respir Crit Care Med 2003; 168:A320.